| 1 |
<p><b>NCEs in Development Phase</b></p> |
|
| 2 |
|
<p><b>NCE's in Development Phase</b></p> |
| 3 |
<p><b>PLD-116</b></p> |
<p><b>PLD-116</b></p> |
| 4 |
<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase |
<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase |
| 5 |
I clinical study in Germany in December 2000. Prior to that, all the activities |
I clinical study in Germany in December 2000. Prior to that, all the activities |
| 6 |
necessary to fulfill the requirements for the clinical testing of the compound |
necessary to fulfill the requirements for the clinical testing of the compound |
| 7 |
had been undertaken and the pre-clinical testing completed. The PLD-116 project |
had been undertaken and the pre-clinical testing completed. The PLD-116 project |
| 8 |
team has been established in December 1999, to develop peptide PL-10.1 into |
team has been established in December 1999, to develop peptide PL-10.1 into |
| 9 |
a drug for the treatment of inflammatory bowel disease.</p> |
a drug for the treatment of inflammatory bowel disease. The peptide is derived |
| 10 |
|
from a natural protein and provides a novel anti-inflammatory treatment option |
| 11 |
|
for inflammatory bowel disease.</p> |
| 12 |
<p><b>PLD-117</b></p> |
<p><b>PLD-117</b></p> |
| 13 |
<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication |
<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication |
| 14 |
of cancer chemotherapy, was brought to clinical study trials in the USA in December |
of cancer chemotherapy, was brought to clinical study trials in the USA in December |
| 24 |
to be the first novel oral antifungal for the treatment of Candida infections |
to be the first novel oral antifungal for the treatment of Candida infections |
| 25 |
since the introduction of azoles in the 80's. After completing the preclinical |
since the introduction of azoles in the 80's. After completing the preclinical |
| 26 |
package and successful review of necessary documents by the ethics committee |
package and successful review of necessary documents by the ethics committee |
| 27 |
in Germany, clinical studies started in November. According to the planned time |
in Germany, clinical studies started in November.</p> |
|
schedule, multiple dosing will be finished in May 2001, while the project team |
|
|
will have already begun the proof of concept study, which is anticipated to |
|
|
start in third quarter of 2001.</p> |
|
Parent Directory
| 
Revision Log
| 
Patch